- Home
- PLTR vs MRK Comparison
PLTR vs MRK Comparison
Compare PLTR & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLTR | MRK |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.0B | 268.7B |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | PLTR | MRK |
|---|---|---|
| Price | $135.40 | $121.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 17 |
| Target Price | ★ $192.83 | $125.59 |
| AVG Volume (30 Days) | ★ 34.1M | 6.9M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 3.06% |
| EPS Growth | ★ 231.58 | 8.01 |
| EPS | ★ 0.34 | N/A |
| Revenue | $4,475,446,000.00 | ★ $65,011,000,000.00 |
| Revenue This Year | $65.66 | $3.61 |
| Revenue Next Year | $42.35 | $5.41 |
| P/E Ratio | $416.59 | ★ N/A |
| Revenue Growth | ★ 56.18 | 1.31 |
| 52 Week Low | $122.68 | $76.66 |
| 52 Week High | $207.46 | $125.14 |
Technical Indicators
Market Signals| Indicator | PLTR | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 44.19 | 60.69 |
| Support Level | $127.13 | $112.49 |
| Resistance Level | $152.85 | $124.09 |
| Average True Range (ATR) | 6.72 | 2.82 |
| MACD | 0.27 | 0.45 |
| Stochastic Oscillator | 9.99 | 83.03 |
Price Performance
Historical ComparisonAbout PLTR Palantir Technologies Inc.
Palantir is an artificial intelligence, analytics, and automated decision-making company that leverages data to drive efficiency across its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The company was founded in 2003 and went public in 2020.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).